Ipsen says to seek approval for muscle-spasm drug
PARIS (Reuters) - French drugmaker Ipsen said that it would begin the process of regulatory approval for a muscle-spasm drug, branded Dysport Next Generation, after a liquid-toxin trial showed it was "safe and efficacious".
"On the basis of these results and feedback from the principal investigator of the Phase III study, Ipsen intends to initiate a dialogue with key agencies on the regulatory approach to file the first ready-to-use liquid toxin A in Europe and rest-of-world," Ipsen said.
(Reporting by Lionel Laurent)
- Children's corpses reveal desperate attempts to escape Korean ferry |
- Ukraine's leaders say have U.S. backing to take on 'aggressors' |
- 'Bridgegate' scandal threatens next World Trade Center tower
- Obama reassures Japan, other allies on China as Asia trip begins |
- UPDATE 4-Children's corpses reveal desperate attempts to escape Korean ferry